President Barack Obama's Feb. 8 budget request for fiscal year 2017 slates $75 million in additional funding for FDA for the creation of a virtual Oncology Center of Excellence.
President Barack Obama Feb. 8 unveiled his budget proposal for the 2017 fiscal year—a $4.1 trillion spending blueprint that is unlikely to be passed by a Republican-controlled Congress.
The White House announced a $1 billion initiative Feb. 1 to jumpstart the national cancer moonshot program—an ambitious proposal first announced by President Barack Obama during his final State of the Union address.
This series re-examines the concurrent controversies at the Cancer Prevention and Research Institute of Texas and MD Anderson Cancer Center. This examination is possible in part because of new insight provided by Alfred Gilman, a Nobel laureate who served as the first scientific director of the state institution that distributes $300 million a year. Gilman died on Dec. 23, 2015.
THE OVARIAN CANCER NATIONAL ALLIANCE and the OVARIAN CANCER RESEARCH FUND announced a merger, forming the Ovarian Cancer Research Fund Alliance. The new body will be the largest global organization dedicated to advancing ovarian cancer research.
TARA YATES was named director of communications of the Wistar Institute.
FDA approved Zepatier (elbasvir and grazoprevir) for the treatment of adult patients with chronic hepatitis C virus genotype 1 or 4 infection, with or without ribavirin, following priority review.
FDA approved Halaven (eribulin mesylate) Injection for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen, following priority review.
JUDY KEEN was named director of scientific affairs of the American Society for Radiation Oncology.
CARMEN SOLÓRZANO was named chief of the Division of Surgical Oncology and Endocrine Surgery at Vanderbilt University Medical Center. Solórzano is a professor of Surgery and director of the Endocrine Surgery Center.
